Dr. Louise Provencher is a surgeon-oncologist at the CHU de Québec-Laval University. She is also a clinical researcher at the Research Center of the CHU de Québec-Laval University, and clinical professor at the Laval University School of Medicine. Dr. Provencher is part of the research group of the Centre des Maladies du Sein of CHU de Québec-Laval University.

Dr. Provencher is a scientific committee member at the McPeak-Sirois research group and the CHU de Quebec leader for the National Surgical Adjuvant Breast and Bowel Project.

Using structured breast cancer data

The Centre des Maladies du Sein research team has a comprehensive database of all cancers diagnosed since 1974; more than 12,000 patients are listed. A database of biopsy data from 1999 is also available; data on more than 34,000 biopsies are listed. These databases allow quality publications that modify the management and follow-up of cancers and benign breast diseases.

Offer innovative treatments

The Centre des Maladies du Sein of CHU de Québec-Laval University research group is one of the largest in Canada offering innovative treatments for breast cancer. More than 50 clinical trials are active at all times and are offered to patients who consult at the clinic or are referred by clinics/hospitals in the area. These clinical trials provide access to innovative experimental medications and develop the expertise of our world-renowned oncologists.

Supporting quality of life

The Centre des Maladies du Sein of CHU de Québec-University research group is a pioneer in quality of life studies in breast cancer, from total mastectomy to partial mastectomy, to the use of the cooling cap to counteract hair loss, promoting physical activity to improve survivorship, including optimal preservation of the axillary lymph nodes. The research group is at the forefront of studies promoting quality of life despite the adverse effects of the disease on an individual’s life.

Hôpital Saint-Sacrement
1050, chemin Sainte-Foy
Centre des maladies du sein Deschênes-Fabia
Québec, Québec
Canada G1S 4L8
75 entries « 2 of 8 »

Poirier E, Desbiens C, Poirier B, Boudreau D, Jacob S, Lemieux J, Doyle C, Diorio C, Hogue JC, Provencher L

Characteristics and long-term survival of patients diagnosed with pure tubular carcinoma of the breast.

Journal Article

J Surg Oncol, 117 (6), pp. 1137-1143, 2018, ISSN: 0022-4790.

Abstract | Links:

Furrer D, Jacob S, Michaud A, Provencher L, Lemieux J, Diorio C

Association of Tobacco Use, Alcohol Consumption and HER2 Polymorphisms With Response to Trastuzumab in HER2-Positive Breast Cancer Patients.

Journal Article

Clin Breast Cancer, 18 (4), pp. e687-e694, 2018, ISSN: 1526-8209.

Abstract | Links:

Poirier E, Desbiens C, Poirier B, Boudreau D, Jacob S, Lemieux J, Doyle C, Diorio C, Hogue JC, Provencher L

In response to: Long-term overall survival of patients diagnosed with pure tubular carcinoma of the breast might be affected by increased co-morbidities.

Journal Article

J Surg Oncol, 117 (7), pp. 1615, 2018, ISSN: 0022-4790.

| Links:

Tremblay-LeMay R, Hogue JC, Provencher L, Poirier B, Poirier E, Laberge S, Diorio C, Desbiens C

How Wide Should Margins Be for Phyllodes Tumors of the Breast?

Journal Article

Breast J, 23 (3), pp. 315-322, 2017, ISSN: 1075-122X.

Abstract | Links:

Bell R, Brown J, Parmar M, Toi M, Suter T, Steger GG, Pivot X, Mackey J, Jackisch C, Dent R, Hall P, Xu N, Morales L, Provencher L, Hegg R, Vanlemmens L, Kirsch A, Schneeweiss A, Masuda N, Overkamp F, Cameron D

Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer.

Journal Article

Ann Oncol, 28 (4), pp. 754-760, 2017, ISSN: 0923-7534.

Abstract | Links:

Bouchard-Fortier A, Provencher L, Blanchette C, Diorio C

Prognostic and predictive value of low estrogen receptor expression in breast cancer.

Journal Article

Curr Oncol, 24 (2), pp. e106-e114, 2017, ISSN: 1198-0052.

Abstract | Links:

Pritchard KI, Chia SK, Simmons C, McLeod D, Paterson A, Provencher L, Rayson D

Enhancing Endocrine Therapy Combination Strategies for the Treatment of Postmenopausal HR+/HER2- Advanced Breast Cancer.

Journal Article

Oncologist, 22 (1), pp. 12-24, 2017, ISSN: 1083-7159.

Abstract | Links:

Furrer D, Jacob S, Caron C, Sanschagrin F, Provencher L, Diorio C

Concordance of HER2 Immunohistochemistry and Fluorescence In Situ Hybridization Using Tissue Microarray in Breast Cancer.

Journal Article

Anticancer Res, 37 (6), pp. 3323-3329, 2017, ISSN: 0250-7005.

Abstract | Links:

Gagnon J, Levesque E, Clinical Advisory Committee on Breast Cancer Screening, Prevention, Borduas F, Chiquette J, Diorio C, Duchesne N, Dumais M, Eloy L, Foulkes W, Gervais N, Lalonde L, L'Esperance B, Meterissian S, Provencher L, Richard J, Savard C, Trop I, Wong N, Knoppers BM, Simard J

Recommendations on breast cancer screening and prevention in the context of implementing risk stratification: impending changes to current policies.

Journal Article

Curr Oncol, 23 (6), pp. e615-e625, 2016, ISSN: 1198-0052.

Abstract | Links:

Furrer D, Lemieux J, Cote MA, Provencher L, Laflamme C, Barabe F, Jacob S, Michaud A, Diorio C

Evaluation of human epidermal growth factor receptor 2 (HER2) single nucleotide polymorphisms (SNPs) in normal and breast tumor tissues and their link with breast cancer prognostic factors.

Journal Article

Breast, 30 , pp. 191-196, 2016, ISSN: 0960-9776.

Abstract | Links:

75 entries « 2 of 8 »
Signaler des ajouts ou des modifications

Active projects

  • Centre de recherche du CHU de Québec - Université Laval, Subvention, Centre hospitalier universitaire de Québec - Université Laval, Centres de recherche affiliés, from 2017-01-01 to 2099-12-31
  • Centre de recherche sur le cancer, Subvention, Institutionnel - BDR, BDR - Centres de recherche reconnus, from 1996-05-01 to 2022-06-13
  • Omega-3 fatty acids in the prevention of breast cancer: role of obesity-related markers in breast tissues, Subvention, Instituts de recherche en santé du Canada, Subvention Projet, from 2018-10-01 to 2022-09-30
  • Pilot study of a community pharmacy-based program to enhance adherence to adjuvant endocrine therapy among breast, Subvention, Instituts de recherche en santé du Canada, Subvention Projet, from 2019-10-01 to 2022-02-28
  • Utilisation de l'intelligence artificielle afin de maintenir automatiquement le registre national de suivi en cancer du sein et du projet de recherche en cancer du sein associé, Subvention, Fondation du cancer du sein du Québec, from 2019-01-01 to 2020-12-31

Recently finished projects

  • Effect of environmental contaminants and methylome of breast adipose tissue on aromatase inhibitor efficacy in breast cancer, Subvention, Instituts de recherche en santé du Canada, Volet Projet: Concours pilotes, from 2016-07-01 to 2020-06-30
  • NSABP Breast Cancer Treatment Protocols, Subvention, National Institute of Health (USA), Subvention de recherche, from 1997-02-01 to 2020-01-31
Data provided by the Université Laval research projects registery